Market and Business Impact of the COVID-19 Pandemic
First written in FY2024. 1 of 3 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 105 of 176 companies on the "Worse" side.
38 other companies' latest entry also says "Dropped".
- FY2026DroppedAnnual report
「Going forward, purchase prices for raw materials and components may rise and procurement lead times may lengthen because of yen depreciation, geopolitical risks and the spread of infectious diseases such as COVID-19.」
The standalone disclosure of market weakness, delayed receivables collection and employee infections caused by COVID-19 has been removed; COVID-19 is now cited only as a factor in procurement risk. - FY2025RestatedAnnual report
「However, depending on future infection trends, the Company's business and financial results could be affected by a weak market, delays in collecting receivables due to deteriorating customer results, employee infections and other factors.」
The Company continues to disclose the risk of market and operational effects from COVID-19. - FY2024First statedAnnual report
「However, depending on future infection trends, the Company's business and financial results could be affected by a weak market, delays in collecting receivables due to deteriorating customer results, employee infections and other factors.」
The Company has implemented infection-control measures, including mask wearing and office disinfection.